Table 1.

Clinical outcomes in COU-AA-301 patients with prior endocrine therapy exposure by duration in quartiles

GnRH agonists
		Q1			Q2			Q3			Q4
		≤28 mo			≥29 to ≤45 mo			≥46 to ≤71 mo			>71 mo
Treatment	AA + P		P	AA + P		P	AA + P		P	AA + P		P
	(n = 191)		(n = 87)	(n = 174)		(n = 109)	(n = 191)		(n = 91)	(n = 195)		(n = 89)
Overall survival
HR		0.99			0.61			0.73			0.68
(95% CI)		(0.71–1.37)			(0.46–0.82)			(0.53–1.00)			(0.48–0.97)
Radiographic progression-free survival
HR		0.84			0.65			0.56			0.68
(95% CI)		(0.62–1.13)			(0.49–0.86)			(0.41–0.76)			(0.50–0.91)
Androgen receptor antagonists
		Q1			Q2			Q3			Q4
		≤7 mo			≥8 to ≤16 mo			≥17 to ≤36 mo			>36 mo
Treatment	AA + P		P	AA + P		P	AA + P		P	AA + P		P
	(n = 155)		(n = 95)	(n = 179)		(n = 85)	(n = 167)		(n = 82)	(n = 170)		(n = 82)
Overall survival
HR		0.78			0.99			0.73			0.57
(95% CI)		(0.56–1.08)			(0.71–1.38)			(0.51–1.03)			(0.40–0.81)
Radiographic progression-free survival
HR		0.76			0.66			0.68			0.62
(95% CI)		(0.55–1.05)			(0.49–0.90)			(0.50–0.93)			(0.45–0.86)

AA = abiraterone acetate; CI = confidence interval; GnRH = gonadotropin-releasing hormone; HR = hazard ratio; P = prednisone; Q = quartile.